Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2005-08-30
2005-08-30
Lambkin, Deborah C. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C549S471000
Reexamination Certificate
active
06936638
ABSTRACT:
Compounds which have utility in the treatment of conditions associated with altered mitochondrial function. The compounds have the following structure (I):including stereoisomers, prodrugs, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5and R6are as defined herein. Pharmaceutical compositions containing a compound of structure (I), as well as methods relating to the use thereof, are also disclosed.
REFERENCES:
patent: 3277164 (1966-10-01), Haack et al.
patent: 3692828 (1972-09-01), Onopchenko et al.
patent: 3886162 (1975-05-01), Pfister et al.
patent: 3965146 (1976-06-01), Dahl
patent: 4683244 (1987-07-01), Moeller et al.
patent: 4935240 (1990-06-01), Nakai et al.
patent: 4980372 (1990-12-01), Nakai et al.
patent: 5217994 (1993-06-01), Egbertson et al.
patent: 5426196 (1995-06-01), Fang
patent: 5684015 (1997-11-01), Mederski et al.
patent: 5888941 (1999-03-01), Bartroli et al.
patent: 5990133 (1999-11-01), Gaster et al.
patent: 6262113 (2001-07-01), Widdowson et al.
patent: 6344466 (2002-02-01), Soll et al.
patent: 6680345 (2004-01-01), Linz et al.
patent: 6855341 (2005-02-01), Smith
patent: 253666 (1988-01-01), None
patent: WO 93/24442 (1993-12-01), None
patent: WO 99/36398 (1999-07-01), None
patent: WO 01/04087 (2001-01-01), None
patent: WO 03/080564 (2003-10-01), None
US 6,274,628, 8/2001, Soll et al. (withdrawn)
Andreyev, A. Y. et al., “The ATP/ADP-antiporter is involved in the uncoupling effect of fatty acids on mitochondria,”European Journal of Biochemistry 182: 585-592, 1989.
Beutner, G. et al., “Complexes between porin, hexokinase, mitochondrial creatine kinase and adenylate translocator display properties of the permeability transition pore. Implication for regulation of permeability transition by the kinases,”Bichimica et Biophysica Acta 1368(1): 7-18, 1998.
Boveris and Chance, “The Mitochondrial Generation of Hydrogen Peroxide,”The Biochemical Journal 134(3): 707-716, 1973.
Farrelly, E. et al., “A High-Throughput Assay for Mitochondrial Membrane Potential in Permeabilized Yeast Cells,”Analytical Biochemistry 293(2): 269-276, Jun. 15, 2001.
Green and Reed, “Mitochondria and Apoptosis,”Science 281:1309-1312, Aug. 28, 1998.
Korshunov, S.S. et al., “Fatty acids as natural uncouplers preventing generation of O2—and H2O2by mitochondria in the resting state,”FEBS Letters 435(2-3): 215-218, 1998.
Korshunov, S.S. et al., “High protonic potential actuates a mechanism of production of reactive oxygen species in mitochondria,”FEBS Letters 416(1): 15-18, 1997.
Kroemer, G. et al., “The Mitochondrial Death/Life Regulator in Apoptosis and Necrosis,”Annual Review of Physiology 60: 619-642, 1998.
Morin D. et al., “Mitochondria as target for antiischemic drugs,”Adv. Drug Deliv. Rev. 49(1-2): 151-174, 2001.
Obatomi and Bach et al., “Inhibition of mitochondrial respiration and oxygen uptake in isolated rat renal tubular fragments by atractyloside,”Toxicology Letters 89(2): 155-161, Dec. 16, 1996.
Skulachev, V.P., “Fatty acid circuit as a physiological mechanism of uncoupling of oxidative phosphorylation,”FEBS Letters 294(3): 158-162, Dec. 1991.
Skulachev, V.P., “Why are mitochondria involved in apoptosis? Permeability transition pores and apoptosis as selective mechanisms to eliminate superoxide-producing mitochondria and cell,”FEBS Letters 397(1): 7-10, 1996.
Wojtczak, L. et al., “Protonophoric Activity of Fatty Acid Analogs and Derivatives in the Inner Mitochondrial Membrane: A Further Argument for the Fatty Acid Cycling Model,”Archives of Biochemistry and Biophysics 357(1): 76-84, Sep. 1, 1998.
Yu, X.X. et al., “Characteriztion of novel UCP5/BMCP1 isoforms and differential regulation of UCP4 and UCP5 expression through dietary or temperature manipulation,”The FASEB Journal 14: 1611-1618, Aug. 2000.
Syamal and Singh, “Synthesis and Characterization of New Polymer Supported Chelating Resins,”Journal Polymer Mater. 6: 175-179, 1989.
Tait, B.D. et al., “Catechol Based Inhibitors of 15-Lipoxygenase,”Bioorganic&Medicinal Chemistry Letters 6(1): 93-96, 1996.
Tun , F. et al., “A Synthetic Approach Towards Homotrinuclear Complexes: Design of Mn(II), Cu(II) and Zn(II) Complexes Using a New Unsymmetrical Tetradenate Ligand,”Revue Roumaine de Chimie 42(7): 579-585, 1997.
Ahlijanian Michael K.
Ghosh Soumitra S.
Liras Spiros J.
Pei Yazhong
Tang Xiao-Qing
Lambkin Deborah C.
Migenix Corp.
Pfizer Inc.
LandOfFree
Ligands of adenine nucleotide translocase (ANT) and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ligands of adenine nucleotide translocase (ANT) and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ligands of adenine nucleotide translocase (ANT) and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3439930